Literature DB >> 28265736

Extralevator Abdominal Perineal Excision Versus Standard Abdominal Perineal Excision: Impact on Quality of the Resected Specimen and Postoperative Morbidity.

Angelita Habr-Gama1,2, Guilherme P São Julião1, Adrian Mattacheo1, Luiz Felipe de Campos-Lobato1, Edgar Aleman1, Bruna B Vailati1, Joaquim Gama-Rodrigues1,2, Rodrigo Oliva Perez3,4,5.   

Abstract

BACKGROUND: Abdominal perineal excision (APE) has been associated with a high risk of positive circumferential resection margin (CRM+) and local recurrence rates in the treatment of rectal cancer. An alternative extralevator approach (ELAPE) has been suggested to improve the quality of resection by avoiding coning of the specimen decreasing the risk of tumor perforation and CRM+. The aim of this study is to compare the quality of the resected specimen and postoperative complication rates between ELAPE and "standard" APE.
METHODS: All patients between 1998 and 2014 undergoing abdominal perineal excision for primary or recurrent rectal cancer at a single Institution were reviewed. Between 1998 and 2008, all patients underwent standard APE. In 2009 ELAPE was introduced at our Institution and all patients requiring APE underwent this alternative procedure (ELAPE). The groups were compared according to pathological characteristics, specimen quality (CRM status, perforation and failure to provide the rectum and anus in a single specimen-fragmentation) and postoperative morbidity.
RESULTS: Fifty patients underwent standard APEs, while 22 underwent ELAPE. There were no differences in CRM+ (10.6 vs. 13.6%; p = 0.70) or tumor perforation rates (8 vs. 0%; p = 0.30) between APE and ELAPE. However, ELAPE were less likely to result in a fragmented specimen (42 vs. 4%; p = 0.002). Advanced pT-stage was also a risk factor for specimen fragmentation (p = 0.03). There were no differences in severe (Grade 3/4) postoperative morbidity (13 vs. 10%; p = 0.5). Perineal wound dehiscences were less frequent among ELAPE (52 vs 13%; p < 0.01). Despite short follow-up (median 21 mo.), 2-year local recurrence-free survival was better for patients undergoing ELAPE when compared to APE (87 vs. 49%; p = 0.04).
CONCLUSIONS: ELAPE may be safely implemented into routine clinical practice with no increase in postoperative morbidity and considerable improvements in the quality of the resected specimen of patients with low rectal cancers.

Entities:  

Mesh:

Year:  2017        PMID: 28265736     DOI: 10.1007/s00268-017-3963-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  25 in total

1.  Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.

Authors:  Joakim Folkesson; Helgi Birgisson; Lars Pahlman; Bjorn Cedermark; Bengt Glimelius; Ulf Gunnarsson
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Low rectal cancer: a call for a change of approach in abdominoperineal resection.

Authors:  Iris D Nagtegaal; Cornelius J H van de Velde; Corrie A M Marijnen; Jan H J M van Krieken; Philip Quirke
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

3.  Prone or lithotomy positioning during an abdominoperineal resection for rectal cancer results in comparable oncologic outcomes.

Authors:  Luiz Felipe de Campos-Lobato; Luca Stocchi; David W Dietz; Ian C Lavery; Victor W Fazio; Matthew F Kalady
Journal:  Dis Colon Rectum       Date:  2011-08       Impact factor: 4.585

4.  Abdominoperineal excision: evolution of a centenary operation.

Authors:  Fábio Guilherme Campos; Angelita Habr-Gama; Sergio Carlos Nahas; Rodrigo Oliva Perez
Journal:  Dis Colon Rectum       Date:  2012-08       Impact factor: 4.585

5.  Favorable pathologic and long-term outcomes from the conventional approach to abdominoperineal resection.

Authors:  David E Messenger; Zane Cohen; Richard Kirsch; Brenda I O'Connor; J Charles Victor; Harden Huang; Robin S McLeod
Journal:  Dis Colon Rectum       Date:  2011-07       Impact factor: 4.585

6.  Multicentre study of circumferential margin positivity and outcomes following abdominoperineal excision for rectal cancer.

Authors:  R P Kennelly; A C Rogers; D C Winter
Journal:  Br J Surg       Date:  2012-11-12       Impact factor: 6.939

7.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

8.  Abdominoperineal resection is associated with poor oncological outcome.

Authors:  W L Law; K W Chu
Journal:  Br J Surg       Date:  2004-11       Impact factor: 6.939

9.  Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer.

Authors:  Nicholas P West; Paul J Finan; Claes Anderin; Johan Lindholm; Torbjorn Holm; Philip Quirke
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544

10.  Extralevator abdominoperineal excision (ELAPE) for rectal cancer--short-term results from the Swedish Colorectal Cancer Registry. Selective use of ELAPE warranted.

Authors:  Mattias Prytz; Eva Angenete; Jan Ekelund; Eva Haglind
Journal:  Int J Colorectal Dis       Date:  2014-06-21       Impact factor: 2.571

View more
  8 in total

1.  The Estimate of the Impact of Coccyx Resection in Surgical Field Exposure During Abdominal Perineal Resection Using Preoperative High-Resolution Magnetic Resonance.

Authors:  Guilherme Pagin São Julião; Cinthia D Ortega; Bruna Borba Vailati; Francisco A B Coutinho; Gustavo Rossi; Angelita Habr-Gama; Laura Melina Fernandez; Sérgio Eduardo Alonso Araújo; Gina Brown; Rodrigo Oliva Perez
Journal:  World J Surg       Date:  2018-11       Impact factor: 3.352

2.  Further insights into the treatment of perineal hernia based on a the experience of a single tertiary centre.

Authors:  R D Blok; T P A Brouwer; S Sharabiany; G D Musters; R Hompes; W A Bemelman; P J Tanis
Journal:  Colorectal Dis       Date:  2020-01-23       Impact factor: 3.788

Review 3.  Extralevator abdominoperineal excision for advanced low rectal cancer: Where to go.

Authors:  Yu Tao; Jia-Gang Han; Zhen-Jun Wang
Journal:  World J Gastroenterol       Date:  2020-06-14       Impact factor: 5.742

4.  Transperineal minimally invasive APE: preliminary outcomes in a multicenter cohort.

Authors:  S E van Oostendorp; S X Roodbeen; C C Chen; A Caycedo-Marulanda; H M Joshi; P J Tanis; C Cunningham; J B Tuynman; R Hompes
Journal:  Tech Coloproctol       Date:  2020-06-16       Impact factor: 3.781

Review 5.  Perineal Wound Closure Following Abdominoperineal Resection and Pelvic Exenteration for Cancer: A Systematic Review and Meta-Analysis.

Authors:  Etienne Buscail; Cindy Canivet; Jason Shourick; Elodie Chantalat; Nicolas Carrere; Jean-Pierre Duffas; Antoine Philis; Emilie Berard; Louis Buscail; Laurent Ghouti; Benoit Chaput
Journal:  Cancers (Basel)       Date:  2021-02-10       Impact factor: 6.639

Review 6.  Surgical Treatment of Low-Lying Rectal Cancer: Updates.

Authors:  Cristopher Varela; Nam Kyu Kim
Journal:  Ann Coloproctol       Date:  2021-12-22

7.  Extralevator abdominoperineal excision versus abdominoperineal excision for low rectal cancer: a meta-analysis.

Authors:  Xin-Yu Qi; Ming Cui; Mao-Xing Liu; Kai Xu; Fei Tan; Zhen-Dan Yao; Nan Zhang; Hong Yang; Cheng-Hai Zhang; Jia-Di Xing; Xiang-Qian Su
Journal:  Chin Med J (Engl)       Date:  2019-10-20       Impact factor: 2.628

8.  Influence of tumor location on short- and long-term outcomes after laparoscopic surgery for rectal cancer: a propensity score matched cohort study.

Authors:  Hong Yang; Zhendan Yao; Ming Cui; Jiadi Xing; Chenghai Zhang; Nan Zhang; Maoxing Liu; Kai Xu; Fei Tan; Xiangqian Su
Journal:  BMC Cancer       Date:  2020-08-14       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.